Xeris Biopharma Holdings (XERS) Net Income towards Common Stockholders (2020 - 2025)
Historic Net Income towards Common Stockholders for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $621000.0.
- Xeris Biopharma Holdings' Net Income towards Common Stockholders rose 10394.59% to $621000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 7521.91%. This contributed to the annual value of -$54.8 million for FY2024, which is 1191.71% up from last year.
- Per Xeris Biopharma Holdings' latest filing, its Net Income towards Common Stockholders stood at $621000.0 for Q3 2025, which was up 10394.59% from -$1.9 million recorded in Q2 2025.
- In the past 5 years, Xeris Biopharma Holdings' Net Income towards Common Stockholders ranged from a high of $621000.0 in Q3 2025 and a low of -$50.8 million during Q4 2021
- For the 5-year period, Xeris Biopharma Holdings' Net Income towards Common Stockholders averaged around -$18.2 million, with its median value being -$16.8 million (2023).
- Per our database at Business Quant, Xeris Biopharma Holdings' Net Income towards Common Stockholders crashed by 13237.41% in 2021 and then soared by 10394.59% in 2025.
- Xeris Biopharma Holdings' Net Income towards Common Stockholders (Quarter) stood at -$50.8 million in 2021, then skyrocketed by 74.54% to -$12.9 million in 2022, then decreased by 3.56% to -$13.4 million in 2023, then surged by 61.81% to -$5.1 million in 2024, then surged by 112.15% to $621000.0 in 2025.
- Its last three reported values are $621000.0 in Q3 2025, -$1.9 million for Q2 2025, and -$9.2 million during Q1 2025.